In conclusion, the meta-analysis of the present study demonstrated that the addition of sorafenib to selected first or second-line chemotherapies provides statistically significant improvements in PFS and TTP for the treatment of HER2-negative ABC. The gene discussed is ERBB2; the disease is aneurysmal bone cyst.